1 **COA5 has an essential role in the early stage of mitochondrial complex IV** 2 **assembly** 3 4 Jia Xin Tang^{1#}, Alfredo Cabrera-Orefice², Jana Meisterknecht², Lucie S. Taylor^{1,3}, 5 Geoffray Monteuuis⁴, Maria Ekman Stensland⁵, Adam Szczepanek¹, Karen Stals⁶, 6 James Davison^{7,8}, Langping He³, Sila Hopton³, Tuula A. Nyman⁵, Christopher B. 7 Jackson 4 , Angela Pyle 1 , Monika Winter 1,9 , Ilka Wittig 2 and Robert W. Taylor 1,3* 8 9 10 ¹ Mitochondrial Research Group, Translational and Clinical Research Institute, Faculty of 11 Medical Sciences, Newcastle University, Newcastle upon Tyne, UK ² Functional Proteomics Center, Institute for Cardiovascular Physiology, Goethe University, 13 Frankfurt am Main, Germany 14 ³ NHS Highly Specialised Rare Mitochondrial Disorders Service, Newcastle upon Tyne 15 Hospitals, NHS Foundation Trust, Newcastle upon Tyne, UK 16 ⁴ Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of 17 Helsinki, Helsinki, Finland ⁵ 18 Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo 19 University Hospital, Oslo, Norway 20 ⁶ Department of Molecular Genetics, Royal Devon and Exeter NHS Foundation Trust, Exeter, 21 UK 22 ⁷ Department of Paediatric Metabolic Medicine, Great Ormond Street Hospital for Children 23 NHS Foundation Trust, UK 24 ⁸ National Institute of Health Research, Great Ormond Street Hospital Biomedical Research 25 Centre, London, UK 26 ⁹ Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria 27 University, Newcastle upon Tyne, UK 28 29 30 31 # **Present address:** Department of NanoBiophotonics, Max Planck Institute for 32 Multidisciplinary Sciences, Göttingen, Germany 33 34 35 36 * **Correspondence:** robert.taylor@ncl.ac.uk 37 38 39 **Running title:** The role of COA5 in complex IV assembly 40 41 42 **Character count:** 50 916

43 **Abstract**

44 Pathogenic variants in cytochrome *c* oxidase assembly factor 5 (COA5), a proposed 45 complex IV (CIV) assembly factor, have been shown to cause clinical mitochondrial disease 46 with two siblings affected by neonatal hypertrophic cardiomyopathy manifesting a rare, 47 homozygous *COA5* missense variant (NM_001008215.3: c.157G>C, p.Ala53Pro). The most 48 striking observation in the affected individuals was an isolated impairment in the early stage 49 of mitochondrial CIV assembly. In this study, we report an unrelated family in who we have 50 identified the same *COA5* variant with patient-derived fibroblasts and skeletal muscle 51 biopsies replicating an isolated CIV deficiency. A CRISPR/Cas9-edited homozygous *COA5* 52 knockout U2OS cell line with similar biochemical profile was generated to interrogate the 53 functional role of the human COA5 protein. Mitochondrial complexome profiling pinpointed a 54 role for COA5 in early CIV assembly, more specifically, its involvement in the stage between 55 MTCO1 maturation and the incorporation of MTCO2. We therefore propose that the COA5 56 protein plays an essential role for the biogenesis of MTCO2 and its integration into the early 57 CIV assembly intermediate for downstream assembly of the functional holocomplex.

58

59 **Keywords:** COA5 / Complex IV / complexome profiling / mitochondria / OXPHOS assembly

60 **Introduction**

61 Mitochondria synthesise cellular energy in the form of adenosine triphosphate (ATP) 62 via oxidative phosphorylation (OXPHOS), comprising four respiratory chain complexes and 63 the F1FO ATP synthase. Cytochrome *c* oxidase (COX), also known as complex IV (CIV), is 64 the terminal electron acceptor of the respiratory chain which catalyses the reduction of 65 molecular oxygen to water. CIV couples this redox reaction to the translocation of protons 66 across the inner mitochondrial membrane, thus contributing to the generation of the proton-67 motive force harnessed by the F_1F_0 ATP synthase to generate ATP.

68 CIV is comprised of 14 protein subunits of dual genetic origin; the three core subunits 69 (MTCO1, MTCO2 and MTCO3) are all mitochondrially-encoded while the remaining subunits 70 are encoded by the nuclear genome (Kadenbach, 2017; Wikström *et al*, 2018). Remarkably, 71 CIV possesses two redox active copper centres (binuclear Cu_A and mononuclear Cu_B 72 centres) and two haem groups (haem *a* and haem *a3*) (Wikström *et al.*, 2018). These redox 73 active cofactors are crucial for electron transfer within CIV which entails: (i) the receipt of 74 electrons from reduced cytochrome c by the Cu_A centre in the MTCO2 subunit, (ii) 75 subsequent delivery of the electron by the haem *a* group in membrane-spanning MTCO1 76 subunit to (iii) the oxygen-reducing haem a_x Cu_B centre (Belevich *et al*, 2006; Kirchberg *et al*, 77 2012; Muramoto *et al*, 2010). These reactions result in the pumping of a total of four protons 78 per oxygen molecule into the mitochondrial intermembrane space (IMS).

79 As a consequence, an intricate assembly machinery has been generally described 80 for complex IV on a modular basis centred around the three catalytic subunits: MTCO1, 81 MTCO2 and MTCO3 with over 20 unique assembly factors of CIV having been characterised 82 to date (Signes & Fernandez-Vizarra, 2018; Vidoni *et al*, 2017; Watson & McStay, 2020). 83 These assembly factors are not only involved in the sequential incorporation of the protein 84 subunits but also crucial for auxiliary processes such as translational regulation, protein 85 stabilisation as well as the insertion of cofactors and prosthetic groups (Povea-Cabello *et al*, 86 2024; Watson & McStay, 2020).

Tang, *et al*. Page 3

87 The cytochrome *c* oxidase assembly factor 5 (*COA5*) gene (RefSeq: 88 NM_001008215.3), previously denoted as *C2orf64*, was first reported in humans when a 89 homozygous missense variant (c.157G>C, p.Ala53Pro) in this gene was shown to cause 90 mitochondrial disease. Biochemical studies of patient-derived fibroblasts revealed isolated 91 COX deficiency, more specifically the accumulation of CIV assembly intermediates and 92 decreased levels of fully assembled CIV holocomplexes, leading the authors to hypothesise 93 that COA5 is involved in the early stages of CIV assembly (Huigsloot *et al*, 2011). However, 94 earlier studies carried out using the yeast orthologue of human COA5 protein, Pet191, also 95 suggested a putative role in CIV assembly but with no impact on COX translation and copper 96 metalation of the protein (Khalimonchuk *et al*, 2008; McEwen *et al*, 1993; Tay *et al*, 2004). 97 Interestingly, contradicting evidence have been published with regards to the mitochondrial 98 localisation of the Pet191 protein despite being a member of the twin $CX₉C$ protein family 99 that are often found to be dependent on the Mitochondrial Intermembrane space Import and 100 Assembly (MIA) pathway (Bragoszewski *et al*, 2013; Khalimonchuk *et al.*, 2008).

101 Here we present an unrelated family in which a clinically affected child harbours the 102 identical *COA5* missense variant, identified by trio whole exome sequencing (Longen *et al*). 103 We generated a CRISPR/Cas9-mediated *COA5* knockout (*COA5*^{KO}) cell line to elucidate the 104 role of COA5 in CIV assembly and its implications on mitochondrial health and disease, 105 utilising an array of biochemical tools including mitochondrial complexome profiling.

107 **Results**

108 *Clinical summary and genomic studies*

109 A female neonate born to second cousin parents presented with tachypnoeic 110 episodes on the first day of life. Blood lactate was elevated at variable levels between 2.5 to 111 11 mmol/L. Clinical examination detected hyperdynamic precordium with loud second heart 112 sound and subsequent echocardiography indicated significant biventricular hypertrophic 113 cardiomyopathy with septal hypertrophy and non-compaction appearance of the myocardium. 114 Due to worsening respiratory distress, she was intubated and given inotropic support after 115 birth before being discharged. Liver function tests were abnormal with increased 116 echogenicity of liver on ultrasound. Neuroimaging of the brain was normal. Focused 117 metabolic biochemical investigations identified elevated urinary lactate and ethylmalonic acid. 118 Clinical care was directed to symptomatic management only when a presumptive diagnosis 119 of mitochondrial disorder with hypertrophic cardiomyopathy was made having identified 120 evidence of significant complex IV activity deficiency on muscle biopsy as detailed below. 121 She was readmitted several weeks later with further deterioration of respiratory distress 122 concurrent with a rhinovirus infection, poor cardiac function and severe lactic acidosis and 123 sadly passed away.

124 Molecular genetic testing eliminated pathogenic mitochondrial DNA (mtDNA) variants 125 following a complete analysis of the mitochondrial genome. Trio whole exome sequencing 126 conducted at the Exeter Genomics Laboratory identified a previously reported *COA5* variant 127 (c.157G>C, p.Ala53Pro), confirming both parents to be heterozygous carriers (**Fig 1A**) 128 (Chen *et al*, 2023; Huigsloot *et al.*, 2011). The homozygous *COA5* missense variant has 129 been recorded on ClinVar as a pathogenic variant associated with isolated COX deficiency 130 (https://www.ncbi.nlm.nih.gov/clinvar/variation/31087/). The c.157G>C *COA5* variant causes 131 an amino acid change from alanine to proline at position 53 of the COA5 protein, which is 132 located within the $CX₉C$ domain that has suggested linkage to mitochondrial protein 133 localisation (Gladyck *et al*, 2021) (**Fig 1B**). The alanine residue is not conserved across

134 species and is only shared between human and zebrafish (**Fig 1B**). Whilst the application of 135 several *in silico* pathogenicity prediction tools suggested the c.157G>C *COA5* variant to be 136 damaging, the REVEL meta-predictor score was below the recommended threshold for this 137 variant, necessitating further study (Ioannidis *et al*, 2016).

138 *Patient-derived muscle biopsies and fibroblasts displayed isolated complex IV*

139 *deficiency*

140 Histochemical analysis of skeletal muscle cryosections from the patient indicated a 141 moderate CIV deficiency in all fibres (**Fig 2A**). This was corroborated by quadruple OXPHOS 142 immunofluorescence assay which showed a marked loss of MTCO1 immunoreactivity (**Fig** 143 **2B**) while NDUFB8 (complex I subunit) protein levels were normal (Ahmed *et al*, 2017). The 144 direct measurement of respiratory chain enzyme activities in patient-derived fibroblasts also 145 indicated a severe and isolated complex IV deficiency in the *COA5* patient muscle sample 146 (**Fig 2C**).

147 *Implications of the homozygous COA5 variant on the steady-state level and assembly* 148 *of complex IV*

149 To characterise the pathogenicity of the *COA5* missense variant, SDS-PAGE and 150 BN-PAGE were used to delineate its impact on OXPHOS protein steady-state levels and 151 assembly. Decreased steady-state levels were only observed in CIV subunit, MTCO2 while 152 other OXPHOS complex subunits were unaffected in whole cell lysates of both patient-153 derived fibroblasts and skeletal muscle biopsy (**Figs 3A** and **3C**). Likewise for BN-PAGE, 154 only complex IV assembly was impaired in patient-derived fibroblasts and skeletal muscle 155 whereas the remaining four OXPHOS complexes (CI, CII, CIII and CV) were unaffected, 156 similar to age-matched controls (**Figs 3B** and **3D**). These observations were further 157 supported by proteomic analysis of the immortalised patient fibroblasts which highlighted the 158 isolated CIV deficiency. CIV protein subunits exhibited a statistically significant decrease in

159 protein abundance up to almost four-fold while CI, CII, CIII and CV protein abundance 160 remained unchanged (**Fig 3E**).

161 *Functional characterisation of COA5 in a CRISPR/Cas9 knockout cell line*

162 Both the primary and immortalised patient fibroblasts harbouring the homozygous 163 c.157G>C *COA5* variant displayed arrested cell growth in culture, likely owing to the severe 164 CIV deficiency and therefore making further experimentation challenging in primary 165 fibroblasts. To enable in-depth characterisation of the functional role and the implicated 166 pathogenicity of *COA5*, CRISPR/Cas9 gene editing was utilised to generate a homozygous 167 *COA5* knockout (*COA5^{KO}*) in the immortalised human U2OS cell line for a more stable 168 cellular model system. The *COA5*^{KO} cell line generated contained a homozygous 7 base pair 169 deletion in the *COA5* gene (c.287_290+3del, p.Val61del) as verified by Sanger sequencing 170 (**Figure EV1)**. Western blot analyses of the *COA5*^{KO} cell line also confirmed an isolated CIV 171 defect in terms of protein steady-state level (**Fig 4A-B**) as well as OXPHOS complex 172 assembly (**Fig 4C**), successfully mimicking the biochemical phenotype observed in patient-173 derived biopsies. Interestingly, an accumulation of the complex II subunit, SDHA protein at 174 around 70 kDa was also observed on BN-PAGE analysis of the *COA5*^{KO} cell line which was 175 absent in the isogenic control (**Fig 4C**).

176 **Mitochondrial Complexome Profiling of COA5^{KO} cell line**

177 To define the functional involvement of COA5 in CIV assembly, mitochondrial 178 complexome profiling, which combines BN-PAGE and tandem mass spectrometry (LC-179 MS/MS), was used to determine the presence and arrangement of the OXPHOS system and 180 related protein complexes (Alahmad *et al*, 2020; Alston *et al*, 2018; Cabrera-Orefice *et al*, 181 2022; Lobo‐Jarne *et al*, 2020). This technique enables visualisation of the specific stage of 182 CIV assembly impacted when COA5 is absent using the *COA5*^{KO} cell line and potentially 183 uncovering interacting partners of the COA5 protein to elucidate its functional role.

184 First, complexome profiling (**Fig 5**) confirmed our result on BN-PAGE (**Fig 4**). An 185 increased abundance of respiratory supercomplexes containing complexes I and $III₂$ (S₀: 186 I+III₂) was observed in the *COA5*^{KO} cell line (**Fig 5, right panel**). As observed in BN-PAGE 187 analysis of the *COA5^{KO}* mitochondrial extracts (Fig 4C), accumulation of the SDHA subunit 188 of CII was also detected by complexome profiling at a molecular size of approx 80 -100 kDa 189 (native calibration of soluble complexes), but not in the isogenic control (highlighted in 190 orange box in **Fig EV2, right panel**). Interesting, SDHAF1 and SDHAF2 comigrate at the 191 same range indicating an assembly intermediate (**Fig EV3, right panel, orange box)**. When 192 assessing complex III subunits, a complete loss of the supercomplexes III_2+IV (S₀) was 193 observed in the *COA5^{KO}* cell line (**Fig 5**). Of all the OXPHOS complexes, only complex V 194 content and assembly were unaffected (**Fig 5**).

195 Next, we had a closer look to complex IV subunits and assembly factors. We noted a 196 complete loss of the COA5 protein as the respective 12 kDa protein was not detected in the 197 knockout cell line but clearly present in the isogenic control as highlighted (**Fig 6A,** 198 **highlighted in yellow**). More importantly, the accumulation of early CIV assembly 199 intermediates (**Fig 6A, right panel, green boxed subunits and assembly factors**) and the 200 loss of fully assembled CIV holocomplexes were observed in contrast to the isogenic control 201 cell line (**Fig 6A, left panel**). Interestingly, subunits of the MTCO1 and MTCO2 modules 202 accumulate in this intermediate, suggesting that despite the lack of subunits in the individual 203 modules, further assembly is already taking place. This provides supporting evidence to the 204 putative role of COA5 as an assembly factor in early stages of complex IV biogenesis and 205 the isolated CIV defect resulting from the loss of COA5 protein as observed in biochemical 206 studies of patient-derived cells and tissues (**Fig 3**).

208 **Discussion**

209 This study identified the previously reported c.157G>C, p.Ala53Pro *COA5* variant in 210 another family. The isolated CIV deficiency associated with the *COA5* variant was observed 211 in the patient fibroblasts and skeletal muscle biopsy, firmly supported by unbiased proteomic 212 profiling of the immortalised *COA5* patient fibroblasts as the biochemical signature of COA5 213 deficiency. Most importantly, a CRISPR/Cas9 *COA5*^{KO} cell line enabled further interrogation 214 via complexome profiling, narrowing down the involvement of COA5 protein to a specific 215 stage of CIV biogenesis involving MTCO2 stabilisation and its incorporation into the MTCO1- 216 containing subcomplex. This study pinpoints specific questions that arise with regards to the 217 functional role of the COA5 protein as a CIV assembly factor, which we elaborate on further 218 below.

219 Given that the rare c.157G>C, p.Ala53Pro variant was found only in two incidences 220 where both patients were of identical ethnicity, this could point towards the likelihood of the 221 variant being a founder pathogenic variant within this population. However, this would 222 require further verification through haplotype analysis, necessitating access to patient-223 derived samples from the previous case. Importantly, overlapping clinical and biochemical 224 phenotypes were observed between the proband in this study and the previously reported 225 patient by Huigsloot and colleagues back in 2019 (Huigsloot *et al.*, 2011), further 226 strengthening the claim that the c.157G>C (p.Ala53Pro) *COA5* variant is pathogenic and 227 causative of an isolated mitochondrial complex IV deficiency, associated with loss of steady-228 state COX proteins and a COX assembly defect in isolation **(Fig 2A-C** and **Fig 3**).

229 To further characterise the functional impact of COA5, we generated a 230 CRISPR/Cas9-mediated knockout. The *COA5*^{KO} cells successfully replicated the isolated 231 complex IV deficiency observed in the reported patients by indicating a loss of MTCO2 232 protein but not MTCO1 detected at comparable levels to the isogenic control on SDS-PAGE 233 (**Fig 4A**). While spontaneous degradation of MTCO1 proteins which are unable to be 234 associated with MTCO2 is normally expected, the unaffected steady-state levels of MTCO1

235 suggest the presence of stabilised MTCO1 subunits despite not being assembled into 236 functional holocomplexes. The loss of the fully assembled complex IV in *COA5^{KO}* cells were 237 not only observed in BN-PAGE analysis but also shown in complexome profiling of the 238 *COA5*^{KO} cells. Most strikingly, this has also been similarly observed in a two-dimensional 239 BN-PAGE of patient fibroblast cell line in the previous report which demonstrated elevated 240 levels of MTCO1 subcomplex but a marked decrease in complex IV holocomplex (Huigsloot 241 *et al.*, 2011). Despite this, the remaining OXPHOS complexes (complex I, II, III and V) were 242 unaffected except the unusual accumulation of a protein complex of about 70 kDa detected 243 with SDHA which corresponds to the size of the individual SDHA protein in *COA5*^{KO} cell line.

244 To further infer the role of COA5 protein and its interacting partner, mitochondrial 245 complexome profiling was employed to dissect co-migrating mitochondrial OXPHOS 246 complexes in the $COA5^{KO}$ cell line in comparison to its isogenic control. Notably, the 247 knockout of COA5 protein was confirmed using this method despite the unavailability of a 248 robust antibody for western blotting. Most strikingly, complexome profiling of the *COA5*^{KO} cell 249 line presented evidence of the implication of COA5 in early complex IV assembly, pinpointing 250 its involvement to the stage between MTCO1 maturation and incorporation of MTCO2 into 251 the early assembly intermediate **(Fig 6B)**. This is supported by the following observations: 252 the accumulation of MTCO1-containing subcomplexes (ranging from approximately 100 to 253 300 kDa) which are absent in the isogenic control, (ii) the apparent absence of MTCO2 254 subunit and (iii) the loss of fully assembled complex IV (**Fig 6A**). Notably, higher molecular 255 mass complexes were shown containing complex IV subunits in *COA5^{KO}* and could reflect 256 assembly of intermediates with the supercomplex S_0 scaffold (Fernández-Vizarra & Ugalde, 257 2022). However, these are more likely to be prohibitin complexes, which direct the free 258 complex IV subunits for degradation rather than supercomplex formation since complex IV 259 biogenesis was completely obstructed (**Fig 6A**) (Back *et al*, 2002; Kohler *et al*, 2023; 260 Steglich *et al*, 1999).

261 Furthermore, the higher abundance of complex I subunits, which was also observed 262 in the SDS-PAGE analysis of *COA5^{KO}* cell lysates, suggest an accumulation of 263 supercomplex S_0 (CI+III₂) which could not form a full respirasome in the absence of CIV 264 holocomplexes. Additionally, the complete loss of supercomplex $III₂+IV$ reinforced the impact 265 of *COA5^{KO}* resulting in complex IV loss, hence favouring the formation of supercomplexes 266 only containing complexes I and $III₂$ to mitigate the OXPHOS defect due to the absence of 267 complex IV. Lastly, the accumulation of free SDHA was not seen in the isogenic control. This 268 may either indicate an upregulation of SDHA as a compensatory mechanism due to the 269 OXPHOS defect or an accumulation of a co-migrating complex of SDHA with CII assembly 270 factors, such as SDHAF1 or SDHAF2 (Martínez-Reyes & Chandel, 2020).

271 Nevertheless, the question remains as to how the c.157G>C (p.Ala53Pro) *COA5* 272 variant affects mitochondrial CIV assembly. The variant likely affects the CX₉C motifs of the 273 encoded protein which has been associated with the MIA pathway for IMS localisation 274 despite contradicting theories for its yeast counterpart (Bragoszewski *et al.*, 2013; Gladyck *et* 275 *al.*, 2021; Herrmann & Köhl, 2007; Khalimonchuk *et al.*, 2008; Longen *et al.*, 2009) (**Fig 1B**). 276 The replacement of alanine by proline could potentially introduce a kink to the alpha helices 277 of the protein and consequently hampering correct folding of the protein to facilitate its import 278 (von Heijne, 1991). Consequently, verifying the submitochondrial localisation of COA5 279 protein would be fundamental in further investigation to inform its functional role associated 280 with an early stage of CIV assembly. Nevertheless, structural studies of the impact of the 281 single amino acid change in *COA5*-encoded protein could also be informative for its potential 282 impact on protein folding and subsequent effect onto its correct localisation within the 283 mitochondria.

284 If the COA5 protein is localised to the IMS, as of most mitochondrial proteins with 285 twin $CX₉C$ motifs, it will most likely be involved in the delivery or incorporation of copper 286 atoms into complex IV which takes place in IMS. According to STRING ('**S**earch **T**ool for 287 **R**etrieval of **In**teracting **G**enes/Proteins'; https://string-db.org/), COA5 protein is predicted to

288 interact with protein partners involved in mitochondrial protein import into IMS and COX 289 copper centre integration, though mostly based on text mining rather than experimental data. 290 Besides, the twin $CX₉C$ motifs have also been linked to Cu(I) binding activity through the 291 reduction of disulphide bonding between the cysteine residues, especially for characterised 292 protein involved in COX maturation (Horng *et al*, 2004; Horng *et al*, 2005; Stroud *et al*, 2015). 293 Interestingly, Nývltová and colleagues also suggested a role for COA5 in the stabilisation of 294 what the authors termed 'metallochaperone complexes', comprising COX-specific copper 295 chaperones and haem biosynthesis enzymes required for the maturation and assembly of 296 COX subunits (Nývltová *et al*, 2022). Although beyond the scope of this manuscript, future 297 experiments should focus on interrogating a direct or indirect role of the COA5 protein in the 298 copper metalation of the MTCO2 subunit which, when affected, leads to destabilisation and 299 eventual degradation of the MTCO2 subunit.

300 Nevertheless, the possibility for the role of COA5 in the mitochondrial matrix should 301 not be eliminated before its submitochondrial localisation is confirmed. Recently, Peker and 302 colleagues demonstrated a two-step mitochondrial import pathway where substrates of the 303 disulphide relay system, including twin $CX₉C$ protein family, rely on oxidative folding through 304 the MIA pathway in the IMS prior to their transport into the matrix (Peker *et al*, 2023). Matrix 305 localisation of the protein, however, would point towards an involvement in complex IV 306 biogenesis at the RNA or protein levels. A potential hypothesis is that COA5 could act as a 307 translation factor for MTCO2 expression, similar to the involvement of TACO1 and 308 MITRAC12 (otherwise known as COA3) proteins in the translational regulation of MTCO1 309 protein synthesis (Mick *et al*, 2012; Richman *et al*, 2016; Weraarpachai *et al*, 2009). 310 Moreover, COA5 could also represent a chaperone or stabilising factor for the MTCO2 311 subunit to facilitate its incorporation into MTCO1-containing subcomplex and therefore 312 impacting synthesis and stability of the MTCO2 protein specifically.

313 In conclusion, this study provides insights into a distinct mode of pathological 314 complex IV assembly caused by the assembly factor COA5 which specifically disrupts the

321 **Materials and Methods**

322 *Whole Exome Sequencing*

- 323 Trio WES (https://www.exeterlaboratory.com/genetics/genome-sequencing/) was conducted
- 324 at the Exeter Genomics Laboratory as previously described (Chen *et al.*, 2023).

325 *Histopathological and Biochemical Analyses*

326 10 µm of frozen skeletal muscle sections were used in each assessment. For 327 histopathological studies, H&E staining was employed to determine muscle morphology 328 while sequential COX and SDH histochemistry was used to assess COX activity in muscle 329 fibres. Spectrophotometric measurements of OXPHOS enzyme (complexes I-IV) activities 330 were conducted as described in (Taylor *et al*) relative to citrate synthase activity. Quadruple 331 immunofluorescence assays were carried out by measuring NDUFB8 (CI) and MTCO1 332 (Reddy *et al*) protein abundance against mitochondrial mass marker, porin using in-house 333 analysis software as outlined in (Taylor *et al.*).

334 *Cell Culture*

335 Patient and age-matched control fibroblasts, as well as U2OS cells, were cultured in High 336 Glucose Dulbecco's Modified Eagle Media supplemented with 10% fetal bovine serum, 1X 337 non-essential amino acids, 50 µg/ml penicillin, 50 µg/ml streptomycin and 50 µg/ml uridine.

338 *SDS-PAGE*

339 Cell pellets were harvested when reaching 80-90% confluency and resuspended in lysis 340 buffer $(50 \text{ mM} \text{ Tris-HCl}$ (pH 7.5), 130 mM NaCl, 2 mM $MgCl₂$, 1 mM 341 phenylmethanesulphonyl fluoride, 1% (v/v) NonidetTM P-40 and 1X EDTA free protease 342 inhibitor cocktail). The resuspended cell pellets were incubated on ice for 10 minutes, before 343 harvesting the resultant supernatant from centrifugation at 500 g at 4°C for 5 minutes and
344 the protein concentrations were determined using Bradford assay. 344 the protein concentrations were determined using Bradford assay.

345 Skeletal muscle homogenates were prepared by grinding 20 mg of frozen muscle section 346 into powder using pestle and mortar in liquid nitrogen and resuspended in 347 radioimmunoprecipitation (RIPA) buffer containing 1% Igepal, 1.5% Triton-X-100, 0.5% 348 sodium deoxycholate, 10mM β-mercaptoethanol, 0.1% SDS, 1 mM PMSF and 1X EDTA-free 349 protease inhibitor cocktail. The resuspensions were subjected to a 45-minute incubation on 350 ice followed by three rounds of 15-second homogenisation. The soluble proteins were 351 extracted by centrifugation at 14 000g at 4°C for 10 minutes and protein concentrations were
352 estimated using Pierce™ BCA Protein Assay Kit. 352 estimated using Pierce™ BCA Protein Assay Kit.

353 40 µg of protein extracts were resuspended in 1X Laemmli Sample Buffer and denatured at 354 either 95°C for 5 minutes or 37°C for 15 minutes. The samples were then subjected to 12% 355 SDS-PAGE with the Mini-Protean Tetra Cell system and transferred onto a methanol-356 activated Immobilon-P Polyvinylidene Fluoride (PVDF) membrane using the Mini Trans-Blot 357 Cell system.

358 *BN-PAGE*

359 Cells were pelleted and resuspended in cell homogenisation buffer comprising of 0.6 M 360 mannitol, 1 mM EGTA, 10 mM Tris-HCL pH 7.4, 1 mM PMSF and 0.1 % (v/v) bovine serum 361 albumin (BSA). The cell suspensions were subjected to three rounds of 15x homogenisation 362 in Teflon glass homogenisers at 4°C with intermittent differential centrifugation at 400 g for 363 10 minutes at 4°C to separate cytosolic protein fraction. The mitochondrial fractions were 363 10 minutes at 4°C to separate cytosolic protein fraction. The mitochondrial fractions were
364 pelleted at 11 000 g for 10 minutes at 4°C and washed in cell homogenisation buffer without
365 BSA. 365 BSA.

366 Approximately 40 mg of skeletal muscle sections were processed and homogenised in 367 Muscle Homogenisation Buffer (250 mM sucrose, 20 mM imidazole hydrochloride and 100 368 mM PMSF) and homogenised in Teflon glass Dounce homogeniser for 15 to 20 rounds at 369 4°C. The muscle homogenates were then pelleted at 20 000 g for 10 minutes at 4°C and

370 washed twice with Muscle Homogenisation Buffer before pelleting at 20 000 g for 5 minutes 371 at 4°C.

372 The final pellets were solubilised in 2% n-dodecyl β-D-maltoside (DDM) and subjected to 373 ultracentrifugation at 100 000 g for 15 minutes at 4°C and the supernatants were extracted 374 for protein concentration determination using Pierce™ BCA Protein Assay Kit. About 10 µg of 375 mitochondrial protein complexes were loaded and separated in the precast Native PAGE™ 376 4-16% Bis-Tris 1.0 mm Mini Protein Gel in the XCell SureLock Mini-Cell Electrophoresis 377 System based on manufacturer's protocol. The protein complexes were then 378 immobilised onto an Immobilon-P PVDF membrane using the MiniTrans-Blot Cell system.

379 *Immunoblotting Analysis*

380 The membranes were blocked in 5% milk for an hour at room temperature before 381 immunoblotting with specific primary antibodies and corresponding HRP-conjugated 382 secondary antibodies as listed: OXPHOS cocktail (ab110411, Abcam), MTCO1 (ab14705, 383 Abcam), MTCO2 (ab110258, Abcam), COXIV (ab14744, Abcam), NDUFB8 (ab110242, 384 Abcam), SDHA (ab14715, Abcam), UQCRC2 (ab14745, Abcam), ATP5A (ab14748, Abcam), 385 GAPDH (600004, ProteinTech), VDAC1 (ab14734, Abcam), Polyclonal Rabbit Anti-Mouse 386 Ig/HRP (P0161, Dako) and Polyclonal Swine Anti-Rabbit Ig/HRP (P0399, Dako).

387 Finally, resultant signal was detected using SuperSignal™ West Pico PLUS 388 Chemiluminescent Substrate (Thermo Scientific) and analysed with ChemiDoc® XRS+ 389 Imaging Systems and Image Lab Software (BioRad).

390 *On-beads precipitation and protein digestion*

391 Cell pellets were lysed with 120µl RIPA buffer containing protease and phosphates inhibitors. 392 10µg of protein from all cell lysates were precipitated with 70% acetonitrile onto magnetic 393 beads (MagReSynAmine, Resyn Biosciences). The proteins were washed on the beads with 394 100% acetonitrile, 70% ethanol and then resuspended in 50µl 50mM ammoniumbicarbonate

395 containing 10mM DTT for reduction of cysteines. Samples were incubated at 37 \Box C for 396 40min. Then, to alkylate proteins, 50µl of 30mM IAA in 50mM ammonium bicarbonate was 397 added and samples were incubated at RT in the dark for 30 minutes. 0.5µg trypsin was 398 added to each sample for overnight on-beads protein digestion at 37°C. The resulting 399 peptides were concentrated and desalted on EVOTIPS for mass spectrometry analysis 400 according to the standard protocol from EVOSEP.

401 *LC-MS/MS analysis*

402 LC-MS/MS analysis was carried out using an EVOSEP one LC system (EVOSEP 403 Biosystems, Denmark) coupled to a timsTOF Pro2 mass spectrometer, using a 404 CaptiveSpray nano electrospray ion source (Bruker Corporation, Germany).

405 200 ng of digested peptides were loaded onto a capillary C18 column (15 cm length, 150 μ^m 406 inner diameter, 1.5 μm particle size, EVOSEP, Odense Denmark). Peptides were separated 407 at 40 °C using the standard 30 sample/day method from EVOSEP.

408 The timsTOF Pro2 mass spectrometer was operated in DIA-PASEF mode. Mass spectra for 409 MS were recorded between m/z 100 and 1700. Ion mobility resolution was set to 0.85–1.30 410 V·s/cm over a ramp time of 100 ms. The MS/MS mass range was limited to m/z 475-1000 411 and ion mobility resolution to 0.85-1.27 V s/cm to exclude singly changed ions. The 412 estimated cycle time was 0.95 s with 8 cylces using DIA windows of 25 Da. Collisional 413 energy was ramped from 20eV at 0.60 V s/cm to 59eV at 1.60 V s/cm.

414 Raw data files from LC-MS/MS analyses were submitted to DIA-NN (version 1.8.1) for 415 protein identification and label-free quantification using the library-free function. The UniProt 416 human database (UniProt consortium, European Bioinformatics Institute, EMBL-EBI, UK) 417 was used to generate library in silico from a human FASTA file. Carbamidomethyl (C) was 418 set as a fixed modification. Trypsin without proline restriction enzyme option was used, with

419 one allowed miscleavage and peptide length range was set to 7-30 amino acids. The mass 420 accuracy was set to 15ppm and precursor false discovery rate (FDR) allowed was 0.01 (1%).

421 LC-MS/MS data quality evaluation and statistical analysis was done using software Perseus

422 ver 1.6.15.0CRISPR/Cas9 Gene Knockout

423 Wildtype U2OS cells were resuspended in room-temperature Nucleofector Solution added 424 with Supplement from the Cell Line NucleofectorTM Kit V (Lonza) at a density of 1 x 10⁶ 425 cells per nucleofection reaction. COA5-targeting sgRNA (Sigma) was incubated at room 426 temperature with HiFi Cas9 nuclease at a 1:1.2 molar ratio to form ribonucleoprotein 427 complexes. The sgRNA sequence designed to mediate CRISPR/Cas9 knockout of the 428 COA5 gene is as follows: 5'-TTTTGAGTGTAAAAGATCAG-3'. The sgRNA-Cas9 RNP 429 complexes were nucleofected into wildtype U2OS cells on the NucleofectorTM 2b Device 430 (Lonza). Nucleofected cells were resuspended in growth media as outlined in Section 2.6.1 431 before transferring to a 6-well plate. The cells were incubated at 37°C, 5% CO2 for 48 hours 432 before isolating into single cell clones using FACSAria™ Fusion Flow Cytometer (BD 433 Biosciences) in four 96-well plates. Sanger sequencing chromatographs of the selected 434 single cell clones were analysed using Inference of CRISPR Edit (ICE) analysis (Synthego; 435 https://ice.synthego.com/) to identify isogenic controls and COA5 knockout cell line.

436 *Complexome Profiling (BN-PAGE, Trypsin Digestion, LC-MS/MS, Quantification)*

437 Enriched mitochondrial proteins were extracted from COA5^{KO} and isogenic control cell lines 438 and solubilised with digitonin as described in (Giese et al., 2021). Equal amount of the 439 solubilised mitochondrial protein extracts were subjected to a 3 to 18% acrylamide gradient 440 gel (14cm ×14cm) for BN-PAGE as outlined in (Wittig, Braun and Schägger, 2006). The gel 441 was then stained with Coomassie blue and cut into equal fractions then transferred to 96- 442 well filter plates. The gel fractions were then destained in 50 mM ammoniumbicarbonate 443 (ABC) followed by protein reduction using 10 mM DTT and alkylation in 20 mM 444 iodoacetamide. Protein digestion was carried out in digestion solution (5 ng trypsin/μl in 50

445 mM ABC, 10% acetonitrile (ACN), 0.01% (w/v) ProteaseMAX surfactant (Promega), 1 mM 446 CaCl₂) at 37°C for at least 12 hours. After the recovery in the new 96-well plate, the peptides 447 were dried in a SpeedVac (ThermoFisher) and finally resuspended in 1% ACN and 0.5% 448 formic acid. Nano liquid chromatography and mass spectrometry (nanoLC/MS) was carried 449 out on Thermo Scientific[™] Q Exactive Plus equipped with ultrahigh performance liquid 450 chromatography unit Dionex Ultimate 3000 (ThermoFisher) and a Nanospray Flex Ion-451 Source (ThermoFisher). The MS data was analysed using MaxQuant software at default 452 settings and the recorded intensity-based absolute quantifications (iBAQ) values were 453 normalised to isogenic control cell line.

454

455 **Data Availability**

456 The mass spectrometry proteomics data for label-free whole cell proteomics and 457 complexome profiling produced in this study have been deposited to the ProteomeXchange 458 Consortium via the PRIDE partner repository (Perez-Riverol *et al*, 2022) and assigned the 459 dataset identifier PXD050891 and PXD053461 respectively.

461 **Acknowledgements**

462 RWT is supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the 463 Medical Research Council (MRC) International Centre for Genomic Medicine in 464 Neuromuscular Diseases (MR/S005021/1), the UK NIHR Biomedical Research Centre in 465 Age and Age-Related Diseases award to the Newcastle upon Tyne Hospitals NHS 466 Foundation, the Lily Foundation, LifeArc and the UK NHS Highly Specialised Service for 467 Rare Mitochondrial Disorders. RWT and MW are supported by the Pathology Society; RWT, 468 MW and AP are supported by Mito Foundation. JXT was supported by a PhD studentship 469 from the Lily Foundation and a Newcastle University Overseas Research Studentship award. 470 CBJ is supported by funding from the Academy of Finland (decision #336455), the Magnus 471 Ehrnroot Foundation and the Jane and Aatos Erkko Foundation (#230004). The Proteomics 472 Core Facility, University of Oslo/Oslo University Hospital is supported by the Core Facilities 473 program of the South-Eastern Norway Regional Health Authority, and is a member of the 474 National Network of Advanced Proteomics Infrastructure (NAPI) which is funded by the 475 Research Council of Norway INFRASTRUKTUR-program (project number: 295910). IW is 476 supported by the Deutsche Forschungsgemeinschaft (DFG): SFB1531-S01, project number 477 456687919 and WI 3728/3-1, project number 515944830.

478

479 **Author Contributions**

- 480 **Conceptualization**: AP, MW, IW and RWT
- 481 **Data curation and formal analysis:** JXT, ACO, JM, LST, GM, SKS, AS, KS, LH, SH, TAN
- 482 **Clinical care of the family:** JD
- 483 **Supervision:** AP, MW, CBJ, IW and RWT
- 484 **Drafting the manuscript:** JXT, AP, MW and RWT
- 485 **Critical revision and editing of the manuscript:** all authors
- 486 **Funding acquisition:** AP, MW, IW and RWT

487 **Disclosure and competing interests statement:** The authors declare no conflicts of 488 interest.

489

490 **The Paper Explained**

491 **PROBLEM:**

492 A homozygous *COA5* variant was previously reported to cause a mitochondrial 493 cardiomyopathy phenotype but the role of the COA5 protein is poorly defined despite being 494 proposed to be an assembly factor for cytochrome *c* oxidase (COX), an essential protein of 495 the mitochondrial respiratory chain.

496 **RESULTS**:

497 Through a series of biochemical experiments including LC-MS/MS-based complexome

498 profiling, our study showed that the human COA5 protein is essential for the biogenesis and

499 incorporation of the MTCO2 subunit, specifically, to form functional COX holocomplexes.

500 Additionally, we present an additional case of COA5-related mitochondrial disease,

501 confirming the pathogenicity of the reported homozygous *COA5* variant that leads to

502 mitochondrial dysfunction.

503 **IMPACT:**

504 We have provided additional insights into the functional role of human COA5 protein and its

505 specific implications on early-stage COX assembly, correlating to isolated COX deficiencies

506 observed in patients harbouring a pathogenic, homozygous *COA5* variant.

507

509 **Figure Legends**

510 **Figure 1 – Molecular genetics of the** *COA5* **variant.**

511 **(A)** Partial family pedigree of *COA5* patient showing segregation of the *COA5* variant. **(B)** 512 Schematic representation of the COA5 gene (Ensembl) and its encoded protein (InterPro 513 and UniProt) illustrating the nucleotide or amino acid impacted by the *COA5* variant. The 514 coiled coil-helix-coiled coil helix (CHCH) domain containing twin CX₉C motifs (purple stripes) 515 were illustrated in salmon pink. Amino acid residues at the position affected by the *COA5* 516 variant across different species were highlighted**.**

517 **Figure 2 – Histopathology findings of patient with** *COA***5 variant**

518 **(A)** Histochemical analysis of skeletal muscle section from patient with haematoxylin and 519 eosin (H&E), cytochrome *c* oxidase (COX), succinate dehydrogenase (SDH) and sequential 520 COX-SDH histochemistry. Scale bar = 100 µm; magnification at 10x**. (B)** Quadruple 521 OXPHOS immunofluorescent assay of single skeletal muscle fibres from patient showing 522 immunoreactivity against complex I subunit, NDUFB8 (x-axis) and complex IV subunit, 523 MTCO1 (y-axis) normalised with porin expression as mitochondrial mass marker. Each dot 524 corresponds to a single muscle fibre and beige colour corresponds to normal mitochondrial 525 mass. Muscle fibres with a z-score of less than -3 standard deviation are considered 526 deficient. Bold dashed lines represent the mean expression level in healthy muscle fibres. **(C)** 527 Spectrophotometric measurement of OXPHOS enzyme activities in patient fibroblasts (in red) 528 compared to mean activities in age-matched controls (in blue) shown as 100%. All 529 measurements were normalised to citrate synthase (CS) activity. Error bars represent 530 standard deviations of enzyme activities in control fibroblasts *(n=8)*. Respiratory chain 531 enzyme activities in the patient which exceed control range are marked with an asterisk (*).

532 **Figure 3 – Immunoblotting analyses of COA5 patient-derived fibroblasts and skeletal** 533 **muscle biopsies.**

534 **(A)** SDS-PAGE and immunoblotting analysis of whole protein lysates from *COA5* patient 535 fibroblasts (P) and age-matched controls (C1 and C2) showing steady-state levels of 536 OXPHOS complex subunits. GAPDH and SDHA were used as loading controls *(n=3)*. **(B)** 537 BN-PAGE analysis of mitochondrial-enriched proteins from patient (P) against age-matched 538 controls (C1 and C2) immunodetected against specific OXPHOS complex subunits. SDHA 539 was used as loading control *(n=3)*. **(C)** Western blot analysis of protein extracts from skeletal 540 muscle sections of patient (P) and controls (C1 and C2) with VDAC1 as loading control *(n=1)*. 541 **(D)** BN-PAGE analysis of skeletal muscle mitochondrial extracts derived from patient (P) and

542 age-matched controls (C1 and C2) detecting all five OXPHOS complex subunits with SDHA 543 as loading control *(n=1)*. **(E)** Label-free proteomic profiling of immortalised patient fibroblasts 544 with log-fold change in abundance compared to control. Each data point corresponds to the 545 mean of quadruplicate measurements of identified OXPHOS complex subunits (40 out of 44

- 546 CI subunits, 3 out of 4 CII subunits, 9 out of 10 CIII subunits, 11 out of 19 CIV subunits and
- 547 15 out of 20 CV subunits were analysed.)

Figure 4 – Western Blot analyses of COA5*KO* 548 **cell line against isogenic control.**

549 SDS-PAGE of whole cell lysates against **(A)** complex IV subunits including MTCO1, MTCO2 550 and COXIV *(n=2)* and **(B)** protein subunits of all five OXPHOS complexes using OXPHOS 551 cocktail antibody *(n=2)*. GAPDH and/or SDHA were used as loading controls. **(C)** BN-PAGE 552 of mitochondrial-enriched lysates immunoblotted against all five OXPHOS complexes with

553 SDHA as loading control *(n=3)*.

Figure 5 – Complexome profiling identified decreased complex IV levels in COA5KO 554 555 **compared to wildtype (COA5^{WT}) isogenic control cell line.**

556 Isolated mitochondrial membranes were solubilised with digitonin and protein complexes 557 were separated by BN-PAGE followed by quantitative mass spectrometric analysis. The 558 quantitative data of identified individual subunits were summed up for each OXPHOS 559 complex and normalised to maximum appearance between both cell lines. The data are 560 presented as heat maps and 2D-plots, corresponding to protein components of individual 561 OXPHOS complexes. The size of the complexes ranges from 10000 kDa to 10 kDa (from left 562 to right). The corresponding complexes were highlighted above the heatmap and 2D-plots: 563 fully assembled complex IV holocomplexes (IV), complex III dimer (III₂), supercomplexes of 564 complex III dimers and complex IV (S_s) and supercomplexes containing complex I, complex 565 III dimer (S_0) and complex IV (S_1) .

566 **Figure 6 - Accumulation of early-stage complex IV assembly intermediate**

567 **(A)** The following heatmap illustrates the distribution of complex IV subunits, assembly 568 factors and the prohibitin complex. The subunits and assembly factors of the assembly 569 modules are cultured as follows: MTCO1 module (green), MTCO2 module (purple), MTCO3 570 module (orange) and final subunit (black). The light blue arrows indicate subunits that co-571 migrate with the prohibitin complex. **(B)** A schematic illustration of the sequential assembly 572 intermediates of the CIV holocomplex. Adapted from (Hock *et al*, 2020).

573 **Figure EV1 – Synthego Inference of CRISPR Edits (ICE) analysis of** *COA5* **CRISPR** 574 **knockout and isogenic control cell lines.**

575 **(A)** A homozygous 7bp deletion (c.287_290+3del, p.Val61del) around the expected cut site 576 of the expected cut site of the *COA5*-targeting sgRNA (indicated with black dotted line) was 577 verified, generating a full knockout of the *COA5* gene. Sanger sequencing traces in the 578 bottom panel illustrate the deletion of seven bases in the *COA5*^{KO} cells compared to wildtype 579 sequence shown below which contains protospacer adjacent motif (PAM) site underlined in 580 red dotted line and the sgRNA binding site in black. **(B)** Wildtype sequence was confirmed 581 through Sanger sequencing in the isogenic control cell line selected from the cell population 582 that was nucleofected with Cas9 and sgRNA targeting the *COA5* gene.

583 Figure EV2 – Mitochondrial complexome profiling of *COA5*^{kO} and wildtype (COA5 WT) 584 **isogenic control cell lines.**

585 The data are presented as a heat map, corresponding to protein components of individual 586 OXPHOS complexes. The size of the complexes ranges from 10000 kDa to 10 kDa (from left 587 to right). The corresponding complexes were highlighted above the heatmap as individual 588 subunits, fully assembled complex IV holocomplexes (IV), complex III dimers (III₂), small 589 supercomplex of complex III dimers and complex IV $(S_{s}$, III₂+IV) and supercomplexes 590 containing complex I, complex III dimers (S_0) and complex IV (S_1) . Relative abundance of 591 each protein was represented from low to high according to colour scale illustrated on the 592 bottom right.

593 **Figure EV3 – Complex II assembly intermediates in COA5 KO**

594 The relative protein abundance is presented as a heat map, corresponding to protein 595 components of complex II. The size of the complexes ranges from 10000 kDa to 10 kDa 596 (from left to right) and are given as native membrane (top scale) and soluble (lower scale) 597 protein calibration. The orange box indicates an assembly intermediate in the COA5^{KO} cell 598 line.

599

600

601

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.08.27.24312374;](https://doi.org/10.1101/2024.08.27.24312374) this version posted August 28, 2024. The copyright holder for this preprint

603 **References**

604 Ahmed ST, Alston CL, Hopton S, He L, Hargreaves IP, Falkous G, Oláhová M, McFarland R, 605 Turnbull DM, Rocha MC *et al* (2017) Using a quantitative quadruple immunofluorescent 606 assay to diagnose isolated mitochondrial Complex I deficiency. *Sci Rep* 7: 15676

607 Alahmad A, Nasca A, Heidler J, Thompson K, Oláhová M, Legati A, Lamantea E, 608 Meisterknecht J, Spagnolo M, He L et al (2020) Bi-allelic pathogenic variants in NDUFC2 608 Meisterknecht J, Spagnolo M, He L *et al* (2020) Bi-allelic pathogenic variants in NDUFC2 609 cause early-onset Leigh syndrome and stalled biogenesis of complex I. *EMBO Mol Med* 12: 610 e12619

611 Alston CL, Heidler J, Dibley MG, Kremer LS, Taylor LS, Fratter C, French CE, Glasgow RIC, 612 Feichtinger RG, Delon I *et al* (2018) Bi-allelic Mutations in NDUFA6 Establish Its Role in

613 Early-Onset Isolated Mitochondrial Complex I Deficiency. *Am J Hum Genet* 103: 592-601

614 Back JW, Sanz MA, De Jong L, De Koning LJ, Nijtmans LG, De Koster CG, Grivell LA, Van
615 Der Spek H, Muijsers AO (2002) A structure for the yeast prohibitin complex: Structure Der Spek H, Muijsers AO (2002) A structure for the yeast prohibitin complex: Structure 616 prediction and evidence from chemical crosslinking and mass spectrometry. *Protein Sci* 11: 617 2471-2478

- 618 Belevich I, Verkhovsky MI, Wikström M (2006) Proton-coupled electron transfer drives the 619 proton pump of cytochrome c oxidase. *Nature* 440: 829-832
- 620 Bragoszewski P, Gornicka A, Sztolsztener ME, Chacinska A (2013) The ubiquitin-621 proteasome system regulates mitochondrial intermembrane space proteins. *Mol Cell Biol* 33: 622 2136-2148

623 Cabrera-Orefice A, Potter A, Evers F, Hevler JF, Guerrero-Castillo S (2022) Complexome 624 Profiling—Exploring Mitochondrial Protein Complexes in Health and Disease. *Frontiers in* 625 *Cell and Developmental Biology* 9

- 626 Chen W, Rehsi P, Thompson K, Yeo M, Stals K, He L, Schimmel P, Chrzanowska-627 Lightowlers ZMA, Wakeling E, Taylor RW *et al* (2023) Clinical and molecular characterization 628 of novel FARS2 variants causing neonatal mitochondrial disease. *Mol Genet Metab* 140: 629 107657
- 630 Fernández-Vizarra E, Ugalde C (2022) Cooperative assembly of the mitochondrial 631 respiratory chain. *Trends Biochem Sci* 47: 999-1008
- 632 Gladyck S, Aras S, Hüttemann M, Grossman LI (2021) Regulation of COX Assembly and 633 Function by Twin CX(9)C Proteins-Implications for Human Disease. *Cells* 10
- 634 Herrmann JM, Köhl R (2007) Catch me if you can! Oxidative protein trapping in the 635 intermembrane space of mitochondria. *J Cell Biol* 176: 559-563
- 636 Hock DH, Robinson DRL, Stroud DA (2020) Blackout in the powerhouse: clinical phenotypes 637 associated with defects in the assembly of OXPHOS complexes and the mitoribosome. 638 *Biochemical Journal* 477: 4085-4132
- 639 Horng Y-C, Cobine PA, Maxfield AB, Carr HS, Winge DR (2004) Specific Copper Transfer 640 from the Cox17 Metallochaperone to Both Sco1 and Cox11 in the Assembly of Yeast 641 Cytochrome c Oxidase*. *Journal of Biological Chemistry* 279: 35334-35340
- 642 Horng Y-C, Leary SC, Cobine PA, Young FBJ, George GN, Shoubridge EA, Winge DR (2005) 643 Human Sco1 and Sco2 Function as Copper-binding Proteins*. *Journal of Biological* 644 *Chemistry* 280: 34113-34122
- 645 Huigsloot M, Nijtmans LG, Szklarczyk R, Baars MJ, van den Brand MA, Hendriksfranssen 646 MG, van den Heuvel LP, Smeitink JA, Huynen MA, Rodenburg RJ (2011) A mutation in
- 647 C2orf64 causes impaired cytochrome c oxidase assembly and mitochondrial cardiomyopathy. 648 *Am J Hum Genet* 88: 488-493
- 649 Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, 650 Holzinger E, Karyadi D *et al* (2016) REVEL: An Ensemble Method for Predicting the 651 Pathogenicity of Rare Missense Variants. *Am J Hum Genet* 99: 877-885
- 652 Kadenbach B (2017) Regulation of Mammalian 13-Subunit Cytochrome c Oxidase and 653 Binding of other Proteins: Role of NDUFA4. *Trends Endocrinol Metab* 28: 761-770
- 654 Khalimonchuk O, Rigby K, Bestwick M, Pierrel F, Cobine PA, Winge DR (2008) Pet191 is a 655 cytochrome c oxidase assembly factor in Saccharomyces cerevisiae. *Eukaryot Cell* 7: 1427- 656 1431
- 657 Kirchberg K, Michel H, Alexiev U (2012) Net proton uptake is preceded by multiple proton 658 transfer steps upon electron injection into cytochrome c oxidase. *J Biol Chem* 287: 8187- 8193
- 660 Kohler A, Carlström A, Nolte H, Kohler V, Jung S-j, Sridhara S, Tatsuta T, Berndtsson J, 661 Langer T, Ott M (2023) Early fate decision for mitochondrially encoded proteins by a 662 molecular triage. *Molecular Cell* 83: 3470-3484.e3478
- 663 Lobo-Jarne T, Pérez-Pérez R, Fontanesi F, Timón-Gómez A, Wittig I, Peñas A, Serrano-
664 Lorenzo P. García-Consuegra I. Arenas J. Martín MA et al (2020) Multiple pathways
- 664 Lorenzo P, García‐Consuegra I, Arenas J, Martín MA *et al* (2020) Multiple pathways 665 coordinate assembly of human mitochondrial complex IV and stabilization of respiratory 666 supercomplexes. The EMBO Journal 39: e103912 supercomplexes. The EMBO Journal 39: e103912
- 667 Longen S, Bien M, Bihlmaier K, Kloeppel C, Kauff F, Hammermeister M, Westermann B, 668 Herrmann JM, Riemer J (2009) Systematic analysis of the twin cx(9)c protein family. *J Mol* 669 *Biol* 393: 356-368
- 670 Martínez-Reyes I, Chandel NS (2020) Mitochondrial TCA cycle metabolites control 671 physiology and disease. *Nature Communications* 11: 102
- 672 McEwen JE, Hong KH, Park S, Preciado GT (1993) Sequence and chromosomal localization 673 of two PET genes required for cytochrome c oxidase assembly in Saccharomyces cerevisiae.
674 Curr Genet 23: 9-14 674 *Curr Genet* 23: 9-14
- 675 Mick David U, Dennerlein S, Wiese H, Reinhold R, Pacheu-Grau D, Lorenzi I, Sasarman F, 676
676 Weraarpachai W, Shoubridge Eric A, Warscheid B et al (2012) MITRAC Links Mitochondrial 676 Weraarpachai W, Shoubridge Eric A, Warscheid B *et al* (2012) MITRAC Links Mitochondrial 677 Protein Translocation to Respiratory-Chain Assembly and Translational Regulation. *Cell* 151: 678 1528-1541
- 679 Muramoto K, Ohta K, Shinzawa-Itoh K, Kanda K, Taniguchi M, Nabekura H, Yamashita E, 680 Tsukihara T, Yoshikawa S (2010) Bovine cytochrome c oxidase structures enable O2 681 reduction with minimization of reactive oxygens and provide a proton-pumping gate. *Proc* 682 *Natl Acad Sci U S A* 107: 7740-7745
- 683 Nývltová E, Dietz JV, Seravalli J, Khalimonchuk O, Barrientos A (2022) Coordination of metal 684 center biogenesis in human cytochrome c oxidase. *Nature Communications* 13: 3615
- 685 Peker E, Weiss K, Song J, Zarges C, Gerlich S, Boehm V, Trifunovic A, Langer T, Gehring 686 NH, Becker T *et al* (2023) A two-step mitochondrial import pathway couples the disulfide 687 relay with matrix complex I biogenesis. *Journal of Cell Biology* 222
- 688 Perez-Riverol Y, Bai J, Bandla C, García-Seisdedos D, Hewapathirana S, Kamatchinathan S, 689 Kundu DJ, Prakash A, Frericks-Zipper A, Eisenacher M *et al* (2022) The PRIDE database 690 resources in 2022: a hub for mass spectrometry-based proteomics evidences. *Nucleic Acids* 691 *Res* 50: D543-d552

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.08.27.24312374;](https://doi.org/10.1101/2024.08.27.24312374) this version posted August 28, 2024. The copyright holder for this preprint

692 Povea-Cabello S, Brischigliaro M, Fernández-Vizarra E (2024) Emerging mechanisms in the 693 redox regulation of mitochondrial cytochrome c oxidase assembly and function. *Biochem* 694 *Soc Trans* 52: 873-885

695 Reddy P, Ocampo A, Suzuki K, Luo J, Bacman SR, Williams SL, Sugawara A, Okamura D, 696 Tsunekawa Y, Wu J *et al* (2015) Selective elimination of mitochondrial mutations in the 697 germline by genome editing. *Cell* 161: 459-469

698 Richman TR, Spåhr H, Ermer JA, Davies SMK, Viola HM, Bates KA, Papadimitriou J, Hool 699 LC, Rodger J, Larsson N-G *et al* (2016) Loss of the RNA-binding protein TACO1 causes 700 late-onset mitochondrial dysfunction in mice. *Nature Communications* 7: 11884

701 Signes A, Fernandez-Vizarra E (2018) Assembly of mammalian oxidative phosphorylation
702 complexes I-V and supercomplexes. Essays Biochem 62: 255-270 702 complexes I-V and supercomplexes. *Essays Biochem* 62: 255-270

703 Steglich G, Neupert W, Langer T (1999) Prohibitins regulate membrane protein degradation
704 by the m-AAA protease in mitochondria. Mol Cell Biol 19: 3435-3442 704 by the m-AAA protease in mitochondria. *Mol Cell Biol* 19: 3435-3442

705 Stroud DA, Maher MJ, Lindau C, Vögtle F-N, Frazier AE, Surgenor E, Mountford H, Singh AP, 706 Bonas M, Oeljeklaus S *et al* (2015) COA6 is a mitochondrial complex IV assembly factor 707 critical for biogenesis of mtDNA-encoded COX2. *Human Molecular Genetics* 24: 5404-5415

708 Tay SK, Nesti C, Mancuso M, Schon EA, Shanske S, Bonilla E, Davidson MM, Dimauro S 709 (2004) Studies of COX16, COX19, and PET191 in human cytochrome-c oxidase deficiency. 710 *Arch Neurol* 61: 1935-1937

711 Taylor RW, Pyle A, Griffin H, Blakely EL, Duff J, He L, Smertenko T, Alston CL, Neeve VC, 712 Best A *et al* (2014) Use of Whole-Exome Sequencing to Determine the Genetic Basis of 713 Multiple Mitochondrial Respiratory Chain Complex Deficiencies. *JAMA* 312: 68-77

714 Vidoni S, Harbour ME, Guerrero-Castillo S, Signes A, Ding S, Fearnley IM, Taylor RW, Tiranti

715 V, Arnold S, Fernandez-Vizarra E *et al* (2017) MR-1S Interacts with PET100 and PET117 in 716 Module-Based Assembly of Human Cytochrome c Oxidase. *Cell Reports* 18: 1727-1738

717 von Heijne G (1991) Proline kinks in transmembrane alpha-helices. *J Mol Biol* 218: 499-503

718 Watson SA, McStay GP (2020) Functions of Cytochrome c oxidase Assembly Factors. *Int J*

719 *Mol Sci* 21

720 Weraarpachai W, Antonicka H, Sasarman F, Seeger J, Schrank B, Kolesar JE, Lochmüller H, 721 Chevrette M, Kaufman BA, Horvath R *et al* (2009) Mutation in TACO1, encoding a 722 translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset 723 Leigh syndrome. *Nature Genetics* 41: 833-837

724 Wikström M, Krab K, Sharma V (2018) Oxygen Activation and Energy Conservation by
725 Cytochrome c Oxidase. Chem Rev 118: 2469-2490 725 Cytochrome c Oxidase. *Chem Rev* 118: 2469-2490

A

p.Ala53Pro

A

18

-21

 -15

 -12

 $\frac{1}{9}$

NDUFB8_z

 -6 -3 $\dot{\mathbf{0}}$

3

 -18

0 20 40

Complex I/CS Complex II/CS Complex III/CS Complex IV/CS

B

 $\widehat{\bar{\mathbb{C}}}$ MICO₁ (CIV) NDUFB8 (CI) MTCO1 (CIV) 980 kDa NDUFB8 (CI) ATP5A (CV) ATP5A (CV) SDHA (CII) UQCRC2 **p C1 C2** 980 kDa 140 kDa 500 kDa 220kDa 650 kDa

E

It is made available under a CC-BY-NC-ND-4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit

C

B

Relative abundance

A

WT

$COAS^{KO}$

 $0 \t 0.1 \t 1$

